ConvaTec stock holds steady as investors weigh recent earnings

ConvaTec Group plc (ISIN GB00BD3VFW73) remains a London-listed health care name that investors can frame around its latest reported revenue, margin and cash flow metrics. The shares trade in a market context where the companys own results and guidance matter more than a single day headline.

Latest numbers still matter

ConvaTec reported revenue of USD 2.08 billion for fiscal 2025, with operating profit of USD 365 million and adjusted EBITDA of USD 546 million in the same period. Those figures give investors a dated baseline for the business and make year-on-year comparison the most useful lens.

The same fiscal 2025 reporting also showed free cash flow of USD 280 million and net debt of USD 1.12 billion, two numbers that remain central to how the market reads capital discipline. A business with that mix of profit and balance-sheet data tends to be judged on execution, not narrative.

Growth versus cost discipline

Revenue rose from USD 1.97 billion in fiscal 2024 to USD 2.08 billion in fiscal 2025, which is an increase of about 5.6%. That quantified comparison matters because it shows the company expanded while keeping a clear eye on cash generation.

Adjusted EBITDA of USD 546 million in fiscal 2025 also matters because it sits alongside operating profit of USD 365 million, showing how much cash earnings exceed accounting profit. For investors, the spread between those figures often signals how much room management has to absorb cost pressure.

ConvaTec said in its investor relations materials that it serves patients through categories such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Those segments shape the revenue base that the fiscal 2025 numbers describe.

Care segments drive revenue

The companys product mix is concentrated in recurring-use medical care, which helps explain why revenue and cash flow are the key metrics in each reporting cycle. In fiscal 2025, that model supported USD 2.08 billion in revenue and USD 280 million in free cash flow.

The market will keep watching whether the next update extends the revenue trend beyond the 5.6% increase from fiscal 2024 to fiscal 2025. That comparison is the clearest proof point in the available figures.

Stock context stays linked to the report

ConvaTec stock is listed in London on the FTSE market and the share story remains tied to reported profitability and cash conversion rather than headline product launches. The most recent annual figures give the clearest reference point for the stock narrative.